Article Versions Notes

Isberner N, Gesierich A, Balakirouchenane D, Schilling B, Aghai-Trommeschlaeger F, Zimmermann S, Kurlbaum M, Puszkiel A, Blanchet B, Klinker H, et al. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma. Cancers. 2022; 14(19):4566. https://doi.org/10.3390/cancers14194566

Isberner, Nora, Anja Gesierich, David Balakirouchenane, Bastian Schilling, Fatemeh Aghai-Trommeschlaeger, Sebastian Zimmermann, Max Kurlbaum, Alicja Puszkiel, Benoit Blanchet, Hartwig Klinker, and et al. 2022. "Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma" Cancers 14, no. 19: 4566. https://doi.org/10.3390/cancers14194566

Isberner, N., Gesierich, A., Balakirouchenane, D., Schilling, B., Aghai-Trommeschlaeger, F., Zimmermann, S., Kurlbaum, M., Puszkiel, A., Blanchet, B., Klinker, H., & Scherf-Clavel, O. (2022). Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma. Cancers, 14(19), 4566. https://doi.org/10.3390/cancers14194566